NNVC News

Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo

While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles

The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon

NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak

Form 8-K

NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial

NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering

As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola

Form 8-K

As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo